Towards Healthcare
Head & Neck Cancer Therapeutics Market to Rise at 11.87% CAGR till 2035

Head & Neck Cancer Therapeutics Market Expands With Next Gen ADC Growth

According to market projections, the global head & neck cancer therapeutics market, valued at USD 2.65 billion in 2025, is anticipated to reach USD 8.14 billion by 2035, growing at a CAGR of 11.87% over the next decade. A surge in tobacco and alcohol consumption and the rising cases of HPV are impacting the global expansion. North America registered dominance due to its possession of early access to biologics.

Content

  • Last Updated: 07 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The head & neck cancer therapeutics market is worth USD 2.97 billion in 2026, and by 2035, it is forecasted to hit USD 8.14 billion, registering a CAGR of 11.87% over the decade.

North America is currently leading the head & neck cancer therapeutics market share by 45% due to the highest per-patient expenses, & early access to biologics.

Some key players include Merck & Co., Bristol-Myers Squibb, Roche Genentech, AstraZeneca, and Pfizer.

Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy are the main treatment options.

It is a sophisticated form of external beam radiation therapy that employs a computer to accurately shape the radiation beams to match the tumour three-dimensional form.

US FDA, EMA, NIH, NCBI, CDC, NCI, ClinicalTrials.gov, ACTREC, NCCN, ASHA, AACR.
Any Questions